LEXICON PHARMACEUTICALS, INC. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- LEXICON PHARMACEUTICALS, INC. stock issued during period, value, new issues for the quarter ending 2026-06-30 was -$50.00K.
- LEXICON PHARMACEUTICALS, INC. stock issued during period, value, new issues for the quarter ending 2024-06-30 was -$175.00K, a 100.13% decline year-over-year.
- LEXICON PHARMACEUTICALS, INC. stock issued during period, value, new issues for the quarter ending 2024-03-31 was $241.57M.
- LEXICON PHARMACEUTICALS, INC. stock issued during period, value, new issues for the quarter ending 2023-06-30 was $139.03M.
- LEXICON PHARMACEUTICALS, INC. stock issued during period, value, new issues for fiscal 2024 was $241.32M, a 73.83% increase from fiscal 2023.
- LEXICON PHARMACEUTICALS, INC. stock issued during period, value, new issues for fiscal 2023 was $138.82M, a 47.36% increase from fiscal 2022.
- LEXICON PHARMACEUTICALS, INC. stock issued during period, value, new issues for fiscal 2022 was $94.20M, a 165.43% increase from fiscal 2021.
- LEXICON PHARMACEUTICALS, INC. stock issued during period, value, new issues for fiscal 2021 was $35.49M, a 409.71% increase from fiscal 2020.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2026-06-30 | -$50.00K 10-Q · filed 2026-08-06 | |
| 2024-12-31 | $241.32M 10-K · filed 2026-03-05 | |
| 2024-06-30 | -$175.00K 10-Q · filed 2025-11-06 | |
| 2024-03-31 | $241.57M 10-Q · filed 2025-11-06 | |
| 2023-12-31 | $138.82M 10-K · filed 2026-03-05 | |
| 2023-06-30 | $139.03M 10-Q · filed 2024-11-13 | |
| 2022-12-31 | $94.20M 10-K · filed 2025-03-07 | |
| 2022-09-30 | $94.27M 10-Q · filed 2023-11-08 | |
| 2022-06-30 | $0.00 10-Q · filed 2022-11-09 | |
| 2022-03-31 | $864.00K 10-Q · filed 2023-05-04 | |
| 2021-12-31 | $35.49M 10-K · filed 2024-03-25 | |
| 2021-09-30 | $19.12M 10-Q · filed 2022-11-09 | |
| 2021-06-30 | $8.00K 10-Q · filed 2021-11-09 | |
| 2021-03-31 | $16.40M 10-Q · filed 2022-11-09 | |
| 2020-12-31 | $6.96M 10-K · filed 2023-03-03 | |
| 2020-09-30 | $14.10M 10-Q · filed 2021-11-09 | |
| 2020-06-30 | $0.00 10-Q · filed 2021-11-09 | |
| 2020-03-31 | $2.00K 10-Q · filed 2020-10-30 | |
| 2019-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-11-07 | |
| 2019-03-31 | $0.00 10-Q · filed 2020-10-30 | |
| 2018-09-30 | $158.00K 10-Q · filed 2019-11-07 | |
| 2018-06-30 | $367.00K 10-Q · filed 2019-11-07 | |
| 2018-03-31 | $25.00K 10-Q · filed 2019-11-07 | |
| 2017-09-30 | $54.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-01 | |
| 2017-06-30 | $4.32M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-07-30 | |
| 2017-03-31 | $1.11M 10-Q · filed 2018-05-03 | |
| 2016-09-30 | $2.19M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | |
| 2016-06-30 | $568.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-01 | |
| 2016-03-31 | $184.00K 10-Q · filed 2017-05-04 | |
| 2015-09-30 | $114.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-07 | $201.74M derived: sum of 4 quarters · filed 2017-03-06 |
| 2015-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-04 | $201.78M derived: sum of 4 quarters · filed 2017-03-06 |
| 2015-03-31 | $0.00 10-Q · filed 2016-05-05 | $201.87M derived: sum of 4 quarters · filed 2017-03-06 |
| 2014-12-31 | $201.62M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-06 | $201.95M 10-K · filed 2017-03-06 |
| 2014-09-30 | $163.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-09 | |
| 2014-06-30 | $86.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-07 | |
| 2014-03-31 | $76.00K 10-Q · filed 2015-05-05 | |
| 2013-09-30 | $527.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-06 | $36.87M derived: sum of 4 quarters · filed 2015-03-12 |
| 2013-06-30 | $98.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-07 | $37.13M derived: sum of 4 quarters · filed 2015-03-12 |
| 2013-03-31 | $249.00K 10-Q · filed 2014-05-08 | $37.25M derived: sum of 4 quarters · filed 2015-03-12 |
| 2012-12-31 | $36.00M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-12 | $37.05M 10-K · filed 2015-03-12 |
| 2012-09-30 | $779.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-12 | $161.09M derived: sum of 4 quarters · filed 2014-03-07 |
| 2012-06-30 | $224.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-01 | $160.32M derived: sum of 4 quarters · filed 2014-03-07 |
| 2012-03-31 | $52.00K 10-Q · filed 2013-05-10 | $160.12M derived: sum of 4 quarters · filed 2014-03-07 |
| 2011-12-31 | $160.04M derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-07 | $160.59M 10-K · filed 2014-03-07 |
| 2011-09-30 | $1.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-07 | $552.00K derived: sum of 4 quarters · filed 2013-03-11 |
| 2011-06-30 | $28.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-02 | $551.00K derived: sum of 4 quarters · filed 2013-03-11 |
| 2011-03-31 | $523.00K 10-Q · filed 2012-05-03 | |
| 2010-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-11 | $181.47M 10-K · filed 2013-03-11 |
| 2010-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-01 | |
| 2009-12-31 | $55.17M 10-K · filed 2012-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |